Product Overview
TB 500 is the short name for a synthetic fragment of thymosin beta 4, a protein that occurs naturally in most cells and is associated with actin regulation and cell migration. British Dragon supplies the fragment as a freeze-dried powder in a sealed vial. It is a peptide, not a steroid and not a hormone, and it holds no approval from any medicines regulator, so the accurate way to describe it is a research material for laboratory work.
The reference sheet for this compound is explicit about what is missing. No human half-life is established, no validated human dose exists, and the vendor profile states outright that the human half-life is not known. Everything in the published literature that touches on soft-tissue repair and cell migration comes from animal or cell models. That does not make the peptide useless as a research subject, but it does mean any timeline or dosage figure quoted for a human is an extrapolation rather than a measurement.
What the peptide is not is a growth hormone or a steroid, and the two are frequently confused in online discussion. The growth hormone product stocked in the same catalogue, Somatrobol 100 IU, works on an entirely different pathway, is reconstituted on its own schedule and is never mixed into the same syringe. Hormone items such as Mesterolone, Exemestane or Clomiphene have no place in a peptide study, because a peptide does not touch the hormone axis.
Reconstitution and Research Amounts
Amounts below are supplier research references, not clinical doses, because no clinical dose has been established for this fragment.
| Loading phase | 2.0-2.5 mg twice weekly, which totals 4.0-5.0 mg per week, during weeks one to four |
| Maintenance phase | 2.0-2.5 mg once weekly; at this rate a 5 mg vial covers roughly two to two and a half weeks |
| Block length | Six to eight weeks, followed by a break of comparable duration, which is a supplier recommendation rather than a clinical finding |
| Reconstitution | Add bacteriostatic water to the vial and calculate concentration from the fill volume; the arithmetic is described in the project file base for this peptide |
| Female | The reference sources consulted give no gender-specific figures at all for this peptide |
| Storage of solution | Once mixed, keep the vial cold and consume the contents inside the period stated for it; the shelf life of a specific vial is not confirmed by independent testing |
The arithmetic of a course is worth settling before the first draw, because the vial is small against the loading schedule. Two and a half milligrams twice a week is five milligrams a week, so the loading month consumes about a vial a week on its own, and the maintenance phase that follows stretches one vial across roughly two to two and a half weeks. A six to eight week block therefore runs through several vials, which is a supply calculation rather than a remark about the peptide. Reconstitution is the other variable: concentration is set entirely by the volume of bacteriostatic water added, and nothing printed on the label changes when a different volume goes in.
Suggested Protocols
The arrangements below match how reparative peptides are handled in a research setting. Where a British Dragon page exists it is linked, and no card implies a medical use.
Two positions are usually described rather than one. TB 500 is handled as the systemic half of a repair study, since the fragment is associated with cell migration and actin regulation, while BPC 157 is the local half and is placed near the area of interest. GHK-Cu makes a third position, a copper peptide whose evidence is mostly topical. The three are different molecules with different mechanisms, they are stored and drawn separately, and none of them substitutes for another.
What to Expect
Everything listed is drawn from supplier descriptions and animal work, since human efficacy data is absent.
- Mobility and discomfort. Supplier text describes the first changes in movement and soreness somewhere inside the first one to three weeks.
- Course length. The full supplier protocol runs six to eight weeks; short single shots have no established timeline at all.
- Human data gap. Half-life, safety and effectiveness in people are all unestablished, so every timeline quoted is a supplier figure rather than a trial result.
- Sterility and dosing. As a research product, correct handling and accurate measurement rest entirely with the user.
- Banned in sport. The reference material records the peptide as prohibited by WADA, which matters to any tested athlete.
- Cold chain. The reconstituted solution needs refrigeration; the precise shelf life for our vial is not confirmed by an independent assay.
- Not interchangeable. TB 500 and BPC 157 are different peptides with different mechanisms, and neither substitutes for the other.
Detection is a separate question from prohibition. In veterinary work the N-acetylated metabolite of the fragment, LKKTETQ, has been measured in the urine and plasma of horses, which shows the peptide is broken down and that fragments can be followed in a sample; no human window of the same kind is established anywhere in the sources, so the reference sheet leaves the human figure open rather than attaching a clearance time to it.
Side Effects and Management
Human safety information is limited, so this section names what is reported and flags the gaps instead of closing them.
Handling and Cold Chain
Nothing in this vial touches the gonadal axis, so there is no recovery phase to plan. Handling is where the attention belongs.
